RxION Health review

There is a genuine microdose line here with its own checkout links and its own formulation, and a flat-price commitment stated in the provider's own words — which on this site is read as a cost rather than a comfort, since it means taking less within that range does not reduce the bill. The bigger problem is that the number headlining the microdose page cannot be bought at any tier, and the price it is discounted against was borrowed from a different product. Both standard products headline their six-month prepay rung as though it were monthly, and no milligram figure appears anywhere.

Vs median

$5/mo above the $169 median across the 242 of 373 programs we track that publish a plain monthly rate

Market

$59–$1300/mo is the full published spread in our ranking

Structure

Same price at every dose

Consult

Included in the price

Dietitian

Not included

Labs

Not required

Pricing

Flat at every dose

Price last updated

August 2026

RxION Health does not publicly identify the pharmacy that fills its prescriptions. No bloodwork is required before you start. A clinician review is included in the price.

RxION Health is a direct-to-consumer telemedicine storefront selling compounded semaglutide and tirzepatide, a separate glycine-containing microdose line, branded Wegovy and Zepbound, plus sermorelin, NAD+, glutathione and other injectables. Patients complete an online intake, a licensed U.S. provider reviews it, and medication ships from what the site calls a licensed U.S. pharmacy that it never names. Care is asynchronous with no video visit advertised. The site publishes specific batch-testing claims referencing USP standards for potency, sterility and endotoxin but names no testing laboratory. Service is unavailable in three states, which it states up front.

The microdose page headlines a discounted figure that is not purchasable at any tier — the cheapest real microdose plan is $174, and the advertised price does not exist as a buyable plan

• The struck-through anchor on the microdose page is borrowed from the standard semaglutide one-month price, so the microdose is made to look discounted against a figure that was never its own
• Both standard product pages headline the six-month prepay rung as a per-month price, which is 50% and 39% below the actual month-to-month rate
• No milligram dose is published anywhere on the site, so "lower-than-standard" is the only definition of the microdose a buyer gets
• No pharmacy, compounding facility or testing laboratory is named, and no 503A/503B designation is given
• No legal entity name appears anywhere on the site, including in its legal pages, and no LegitScript seal is displayed
• Compounded GLP-1s are not FDA-approved, and intentional microdosing is off-label and unproven

RxION Health is one of 373 low-dose GLP-1 programs we track, and 242 of them publish a monthly rate you can read before signing up. The ranking lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.

Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

• What the evidence actually shows
• Microdosing semaglutide
• Microdosing tirzepatide
• What a flat price costs at a low dose
• The true annual cost of a plan